Mustang Bio (MBIO) Competitors $0.21 -0.01 (-4.57%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MBIO vs. RVPH, OMGA, ITRM, HCWB, CVM, VRCA, VYNE, RLYB, ANEB, and CLNNShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Reviva Pharmaceuticals (RVPH), Omega Therapeutics (OMGA), Iterum Therapeutics (ITRM), HCW Biologics (HCWB), CEL-SCI (CVM), Verrica Pharmaceuticals (VRCA), VYNE Therapeutics (VYNE), Rallybio (RLYB), Anebulo Pharmaceuticals (ANEB), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. Reviva Pharmaceuticals Omega Therapeutics Iterum Therapeutics HCW Biologics CEL-SCI Verrica Pharmaceuticals VYNE Therapeutics Rallybio Anebulo Pharmaceuticals Clene Reviva Pharmaceuticals (NASDAQ:RVPH) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking. Is RVPH or MBIO more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Mustang Bio's return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -252.53% Mustang Bio N/A -1,243.22%-172.89% Do analysts rate RVPH or MBIO? Reviva Pharmaceuticals presently has a consensus target price of $15.50, suggesting a potential upside of 1,175.72%. Mustang Bio has a consensus target price of $2.00, suggesting a potential upside of 856.94%. Given Reviva Pharmaceuticals' higher probable upside, equities research analysts plainly believe Reviva Pharmaceuticals is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of RVPH or MBIO? 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 27.2% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, RVPH or MBIO? Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$39.26M-$1.11-1.09Mustang BioN/AN/A-$51.60M-$1.56-0.13 Does the media prefer RVPH or MBIO? In the previous week, Reviva Pharmaceuticals and Reviva Pharmaceuticals both had 3 articles in the media. Reviva Pharmaceuticals' average media sentiment score of 0.22 beat Mustang Bio's score of -0.21 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mustang Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in RVPH or MBIO? Mustang Bio received 147 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.00% of users gave Reviva Pharmaceuticals an outperform vote while only 64.26% of users gave Mustang Bio an outperform vote. CompanyUnderperformOutperformReviva PharmaceuticalsOutperform Votes2288.00% Underperform Votes312.00%Mustang BioOutperform Votes16964.26% Underperform Votes9435.74% Which has more risk & volatility, RVPH or MBIO? Reviva Pharmaceuticals has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. SummaryReviva Pharmaceuticals beats Mustang Bio on 10 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.55M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.134.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book-1.1610.126.936.25Net Income-$51.60M$153.61M$119.12M$225.93M7 Day Performance-11.33%-2.00%-1.83%-1.32%1 Month Performance-28.79%-7.47%-3.64%0.60%1 Year Performance-86.34%31.80%31.64%26.23% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio1.9408 of 5 stars$0.21-4.6%$2.00+856.9%-87.6%$10.55MN/A-0.13100RVPHReviva Pharmaceuticals2.6308 of 5 stars$1.22-3.2%$15.50+1,175.7%-71.1%$42.14MN/A0.005OMGAOmega Therapeutics1.479 of 5 stars$0.79+3.9%$9.20+1,064.3%-60.5%$42.08M$3.09M-0.59120ITRMIterum Therapeutics2.0579 of 5 stars$1.63+7.2%$5.00+206.7%+18.1%$41.82MN/A0.0010HCWBHCW Biologics1.1013 of 5 stars$0.95-13.7%N/A-12.3%$41.61M$2.84M0.0040Gap DownCVMCEL-SCIN/A$0.62-3.1%N/A-74.0%$41.17MN/A0.0043Analyst DowngradeVRCAVerrica Pharmaceuticals4.5759 of 5 stars$0.89flat$9.60+981.8%-76.1%$40.58M$5.12M0.0040News CoverageVYNEVYNE Therapeutics2.55 of 5 stars$2.82+3.3%$6.88+143.8%-28.6%$40.27M$420,000.000.0030Analyst ForecastRLYBRallybio2.5309 of 5 stars$0.99+3.1%$9.75+880.8%-59.4%$39.85MN/A0.0040ANEBAnebulo Pharmaceuticals2.5011 of 5 stars$1.52flat$8.00+426.3%-30.9%$39.42MN/A0.004Analyst ForecastShort Interest ↓News CoverageGap UpCLNNClene3.1607 of 5 stars$4.09-12.2%$71.33+1,644.1%-56.6%$38.96M$650,000.000.00100Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies RVPH Alternatives OMGA Alternatives ITRM Alternatives HCWB Alternatives CVM Alternatives VRCA Alternatives VYNE Alternatives RLYB Alternatives ANEB Alternatives CLNN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MBIO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBIO Stock Alerts